Discussion about this post

User's avatar
Christina Zarcadoolas PhD's avatar

Thank you for this thoughtful approach to making the evidence hierarchy more relevant and understandable. I hope to use it ( and reference you) with my grad students.

As for its utility for the general public, I must add a major caveat. There is over 30 years of evidence showing that more than half of the adult US population reads at an 8th grade level and lower and struggles to understand basic health and science information – “low health literacy”. A person’s fundamental literacy and health literacy play an important role in the information they seek out, understand, and use, as well as their health outcomes (Nielsen-Bohlman et al., 2004; Schwartzberg, Van Geest, & Wang, 2005; Zarcadoolas, Pleasant, & Greer, 2006). Other important factors influencing consumers’ understanding are the technological skills they have (technological literacy).

Understanding the basic laws of physics, or distinguishing an opinion piece from a scientific report, is getting harder and harder. Just read many of the articles on the vaccine skeptical Children’s Health Defense Fund site https://childrenshealthdefense.org/ I recently listened to portions of the new ACIP meetings discussing vaccine safety and admit I was tripped up a number of times on whether something presented was valid evidence or cherry-picked.

The enormous and growing gaps between “elites” who understand these elements and the large number in the public sphere who do not is that millions now question the fundamental validity of science and medicine, feel betrayed by experts, and find truth in compelling alternative narratives?

I welcome you and other readers who would like to join me in thinking through, perhaps another period to augment the work you’ve done, targeted at the population I have mentioned here.

Expand full comment
Kristen Panthagani, MD, PhD's avatar

I received a thoughtful question on this post -- what do we do when we don't have the higher quality studies, either because the research isn't being prioritized or the disease is too rare to study in large trials? In that case, I think it's totally reasonable to go with the highest quality data that is available, understanding the limitations. If all that is available is case reports because the disease is so rare -- that's still valuable information, but should also be interpreted with the limitations in mind. Many times clinicians must make decisions with limited information, and a case report can be a valuable tool to help guide them. But if we have better studies, then those take precedence. That's the overall intent of the pyramid: to help people rank the quality of information, not to dismiss every study that doesn't fall into the top of the pyramid.

Expand full comment
7 more comments...

No posts